{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:45:49Z","timestamp":1768009549823,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1053\/j.ackd.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:57:49Z","timestamp":1567195069000},"page":"292-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients"],"prefix":"10.1053","volume":"26","author":[{"given":"Abhijit V.","family":"Kshirsagar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1305-0846","authenticated-orcid":false,"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ackd.2019.05.001_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000074931","article-title":"Iron requirements in hemodialysis","volume":"22","author":"Sargent","year":"2004","journal-title":"Blood Purif"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.001_bib3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0272-6386(82)80059-0","article-title":"Gastrointestinal blood loss in patients with chronic renal failure","volume":"1","author":"Rosenblatt","year":"1982","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"10.1053\/j.ackd.2019.05.001_bib4","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","article-title":"Hepcidin and iron regulation, 10 years later","volume":"117","author":"Ganz","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.001_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2007-12-077388","article-title":"Forging a field: the golden age of iron biology","volume":"112","author":"Andrews","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.001_bib6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"155","key":"10.1053\/j.ackd.2019.05.001_bib7","first-page":"49029","article-title":"HHS. Medicare program; end-stage renal disease prospective payment system. Final rule","volume":"75","year":"2010","journal-title":"Fed Regist"},{"issue":"6","key":"10.1053\/j.ackd.2019.05.001_bib8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1159\/000370334","article-title":"Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status","volume":"40","author":"Thamer","year":"2014","journal-title":"Am J Nephrol"},{"issue":"20","key":"10.1053\/j.ackd.2019.05.001_bib10","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.ackd.2019.05.001_bib11","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ackd.2019.05.001_bib12","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ackd.2019.05.001_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.ackd.2019.05.001_bib14","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.2015.15572","article-title":"Comparative risk of anaphylactic reactions associated with intravenous iron products","volume":"314","author":"Wang","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.001_bib15","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2019.05.001_bib16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locattelli","year":"2013","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.001_bib17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO Clinical Practice Guidelines for Anemia in CKD","volume":"62","author":"Kliger","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.001_bib18","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/j.ajkd.2013.08.001","article-title":"Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guidelines for Anemia in CKD","volume":"62","author":"Moist","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ackd.2019.05.001_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/nep.12139","article-title":"KHA-CARI guideline: use of iron in chronic kidney disease patients","volume":"18","author":"MacGinley","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"10.1053\/j.ackd.2019.05.001_bib20","doi-asserted-by":"crossref","first-page":"h2258","DOI":"10.1136\/bmj.h2258","article-title":"Management of anaemia in chronic kidney disease: summary of updated NICE guidance","volume":"350","author":"Padhi","year":"2015","journal-title":"BMJ"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.001_bib21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2215\/CJN.03970318","article-title":"Safety of dynamic intravenous iron administration strategies in hemodialysis patients","volume":"14","author":"Li","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.001_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpneph0068","article-title":"Drug insight: safety of intravenous iron supplementation with sodium ferric gluconate complex","volume":"2","author":"Michael","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.05.001_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.001_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ndt\/gft443","article-title":"The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients","volume":"29","author":"Zumbrennen-Bullough","year":"2014","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"10.1053\/j.ackd.2019.05.001_bib25","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1681\/ASN.2015010052","article-title":"The labile side of iron supplementation in CKD","volume":"26","author":"Slotki","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2019.05.001_bib26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0378-4274(95)03532-X","article-title":"Toxicity of iron and hydrogen peroxide: the Fenton reaction","volume":"82-83","author":"Winterbourn","year":"1995","journal-title":"Toxicol Lett"},{"issue":"suppl","key":"10.1053\/j.ackd.2019.05.001_bib27","first-page":"S85","article-title":"Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases","volume":"33","author":"Aviram","year":"2000","journal-title":"Free Radic Res"},{"issue":"4852","key":"10.1053\/j.ackd.2019.05.001_bib28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.2834821","article-title":"Toxic DNA damage by hydrogen peroxide through the Fenton reaction in\u00a0vivo and in\u00a0vitro","volume":"240","author":"Imlay","year":"1988","journal-title":"Science"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.001_bib29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1536\/ihj.46.255","article-title":"Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease","volume":"46","author":"Reis","year":"2005","journal-title":"Int Heart J"},{"issue":"6","key":"10.1053\/j.ackd.2019.05.001_bib30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1525-139X.2009.00659.x","article-title":"Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy","volume":"22","author":"Himmelfarb","year":"2009","journal-title":"Semin Dial"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.001_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/femsre\/fuv009","article-title":"Recent developments in understanding the iron acquisition strategies of gram positive pathogens","volume":"39","author":"Sheldon","year":"2015","journal-title":"FEMS Microbiol Rev"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.micinf.2011.11.001","article-title":"A battle for iron: host sequestration and Staphylococcus aureus acquisition","volume":"14","author":"Haley","year":"2012","journal-title":"Microbes Infect"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0092-8674(04)00343-5","article-title":"Balancing acts: molecular control of mammalian iron metabolism","volume":"117","author":"Hentze","year":"2004","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.ackd.2019.05.001_bib34","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0021-9258(19)62337-9","article-title":"Stoichiometric and site characteristics of the binding of iron to human transferrin","volume":"253","author":"Aisen","year":"1978","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1053\/j.ackd.2019.05.001_bib35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbagen.2008.09.004","article-title":"Ferritins: a family of molecules for iron storage, antioxidation and more","volume":"1790","author":"Arosio","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"29","key":"10.1053\/j.ackd.2019.05.001_bib36","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1021\/bi300752r","article-title":"Mechanisms of mammalian iron homeostasis","volume":"51","author":"Pantopoulos","year":"2012","journal-title":"Biochemistry"},{"issue":"19","key":"10.1053\/j.ackd.2019.05.001_bib37","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1056\/NEJMcibr0906391","article-title":"The microcytic red cell and the anemia of inflammation","volume":"361","author":"Keel","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.ackd.2019.05.001_bib38","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib39","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/ndt\/gfr431","article-title":"Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study","volume":"27","author":"Uehata","year":"2012","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.bbagen.2011.07.014","article-title":"Non-transferrin bound iron: a key role in iron overload and iron toxicity","volume":"1820","author":"Brissot","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib42","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbagen.2011.10.013","article-title":"Regulation of iron transport and the role of transferrin","volume":"1820","author":"Gkouvatsos","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1053\/j.ackd.2019.05.001_bib43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbagen.2010.03.011","article-title":"Serum ferritin: past, present and future","volume":"1800","author":"Wang","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.001_bib44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000486968","article-title":"Positive iron balance in chronic kidney disease: how much is too much and how to tell?","volume":"47","author":"Wish","year":"2018","journal-title":"Am J Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2019.05.001_bib45","first-page":"S93","article-title":"Safety of intravenous iron in hemodialysis patients","volume":"21","author":"Li","year":"2017","journal-title":"Hemodial Int"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2215\/CJN.00930118","article-title":"Rest easy with intravenous iron for dialysis patients?: high dose IV iron safety","volume":"13","author":"Li","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ackd.2019.05.001_bib47","first-page":"840","article-title":"Counterpoint: the treatment decision design","volume":"182","author":"Brookhart","year":"2015","journal-title":"Am J\u00a0Epidemiol"},{"issue":"11","key":"10.1053\/j.ackd.2019.05.001_bib48","doi-asserted-by":"crossref","first-page":"e78930","DOI":"10.1371\/journal.pone.0078930","article-title":"Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients","volume":"8","author":"Kshirsagar","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.ackd.2019.05.001_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1471-2369-15-154","article-title":"Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study","volume":"15","author":"Freburger","year":"2014","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.001_bib50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/ndt\/gfu349","article-title":"Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study","volume":"30","author":"Tangri","year":"2015","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"10.1053\/j.ackd.2019.05.001_bib51","doi-asserted-by":"crossref","first-page":"e50295","DOI":"10.1371\/journal.pone.0050295","article-title":"Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients","volume":"7","author":"Kuo","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1053\/j.ackd.2019.05.001_bib52","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2019.05.001_bib53","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2215\/CJN.03370414","article-title":"Intravenous iron exposure and mortality in patients on hemodialysis","volume":"9","author":"Miskulin","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.05.001_bib54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2014.275","article-title":"Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality","volume":"87","author":"Bailie","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2215\/CJN.05390517","article-title":"Safety of intravenous iron in dialysis: a systematic review and meta-analysis","volume":"13","author":"Hougen","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib56","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1681\/ASN.V113530","article-title":"Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients","volume":"11","author":"Besarab","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2215\/CJN.01541005","article-title":"Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial","volume":"1","author":"Singh","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.001_bib58","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.001_bib59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ackd.2019.05.001_bib60","doi-asserted-by":"crossref","first-page":"e114144","DOI":"10.1371\/journal.pone.0114144","article-title":"Iron supplementation and mortality in incident dialysis patients: an observational study","volume":"9","author":"Zitt","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.001_bib61","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/ki.2014.114","article-title":"Association between hemoglobin variability, serum ferritin levels, and adverse events\/mortality in maintenance hemodialysis patients","volume":"86","author":"Kuragano","year":"2014","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ackd.2019.05.001_bib62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2012121164","article-title":"Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients","volume":"24","author":"Brookhart","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.001_bib63","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.ackd.2019.05.001_bib64","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur J Heart Fail"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:00:54Z","timestamp":1761548454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519301132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1548559519301132"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.05.001","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}